retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Eli Lilly infiltrates anti-obesity market

Semaglutide 2.4 mg (Wegovy) is approved under NICE technology appraisal TA875, and tirzepatide (Mounjaro) has also received a NICE technology appraisal for weight management

These trials are evaluating retatrutide across several patient populations, including individuals with obesity, type 2 diabetes, and related metabolic conditions

If it works well enough, this would give doctors a lower-dose option for patients who respond without needing the maximum, similar to how many tirzepatide patients do well on 10 mg without going to 15 mg

In the head-to-head SURMOUNT trial, funded by drug manufacturer Eli Lilly, people who took tirzepatide lost more weight than those who took semaglutide (Ozempic)

T., Batterham, R

F., Ng, T